CatC inhibitor Phase II in bronchiectasis
Research payments
$2,906,071
Through program year 2024, $2,906,071 in research payments was reported against CatC inhibitor Phase II in bronchiectasis, across 110 payments.
- Paid by (largest first)
- Boehringer Ingelheim Pharmaceuticals, Inc.; Boehringer Ingelheim Pharma GmbH & Co.KG; Boehringer Ingelheim International GmbH
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
3 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2024 | Research | $1,321,259 | 39 |
| 2023 | Research | $1,172,989 | 36 |
| 2022 | Research | $411,823 | 35 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
9 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Shahrukh Kureishy McKinney, TX Named on 6 payments
- Mehdi Mirsaeidi Jacksonville, FL Named on 6 payments
- Ryan Klein Newport Beach, CA Named on 6 payments
- Daniel Layish Orlando, FL Named on 6 payments
- Doreen Addrizzo-Harris New York, NY Named on 4 payments
- Bushra Mina Chappaqua, NY Named on 3 payments
- Robert Orr Peoria, AZ Named on 3 payments
- Pamela McShane Tyler, TX Named on 3 payments
- Sean Callahan Seneca, SC Named on 3 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.